Trials / Recruiting
RecruitingNCT06095089
A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer
A Phase 1 Study of JNJ-87189401 (PSMA-CD28 Bispecific Antibody) Combined With JNJ-78278343 (KLK2-CD3 Bispecific Antibody) for Advanced Prostate Cancer
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 250 (estimated)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine the recommended regimen for Phase 2 (RP2Rs) of combination of JNJ-87189401 with JNJ-78278343 (Part 1: dose escalation) and further evaluate the safety at RP2Rs (Part 2: dose expansion) in participants with advanced prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-78278343 | JNJ-78278343 will be administered. |
| DRUG | JNJ-87189401 | JNJ-87189401 will be administered. |
Timeline
- Start date
- 2023-11-01
- Primary completion
- 2027-06-21
- Completion
- 2028-06-28
- First posted
- 2023-10-23
- Last updated
- 2026-02-17
Locations
6 sites across 2 countries: United States, France
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06095089. Inclusion in this directory is not an endorsement.